1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Disease Analysis & Statistics in European Union, January 2020

Chronic Disease Analysis & Statistics in European Union, January 2020

Customer Support

Talk to Ahmad

+1 718 618 4302

All regions

data types

1-30 of about 100 reports

Cymbalta

Cymbalta

  • $ 10000
  • Industry report
  • March 2019

Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since ...

  • Industries : Pathology, Chronic Disease, Therapy, Mental Health
  • Countries : United States, Japan, European Union
Finerenone

Finerenone

  • $ 10000
  • Industry report
  • February 2019

Drug OverviewFinerenone (Bayer) is a third-generation potent and selective oral, non-steroidal mineralocorticoid receptor antagonist (MRA). It blocks the detrimental effects due to over-activation of the ...

  • Industries : Therapy, Chronic Disease, Pathology
  • Countries : United States, Japan, European Union, Europe
Farxiga

Farxiga

  • $ 10000
  • Industry report
  • February 2019

Drug OverviewFarxiga (dapagliflozin; AstraZeneca/Ono Pharmaceutical) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. It is approved for the treatment of type 2 diabetes ...

  • Industries : Chronic Disease, Pathology, Therapy
  • Countries : United States, Japan, European Union
Invokana

Invokana

  • $ 10000
  • Industry report
  • February 2019

Drug OverviewInvokana (canagliflozin; Johnson and Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target ...

  • Industries : Therapy, Chronic Disease
  • Countries : United States, Japan, European Union
Diabetic Nephropathy Market and Forecast Analysis to 2026

Diabetic Nephropathy Market and Forecast Analysis to 2026

  • $ 22000
  • Industry report
  • February 2019

DISEASE OVERVIEWDiabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role o ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, European Union, Japan
Jardiance

Jardiance

  • $ 10000
  • Industry report
  • February 2019

Drug OverviewJardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor originally developed by Boehringer Ingelheim for the treatment of type 2 diabetes. ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Ischemic Stroke Market and Forecast Analysis 2024

Ischemic Stroke Market and Forecast Analysis 2024

  • $ 22000
  • Industry report
  • January 2019

Disease OverviewStroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to ...

  • Industries : Therapy, Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Chronic Heart Failure Market and Forecast Analysis to 2024, Pharma Intelligence

Chronic Heart Failure Market and Forecast Analysis to 2024, Pharma Intelligence

  • $ 22000
  • Industry report
  • January 2019

Disease OverviewChronic heart failure (CHF) is a serious medical condition in which the heart is unable to adequately fill with and eject blood. CHF can result from functional abnormalities such as ventricula ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, European Union, Japan
Osteoporosis Market and Forecast Analysis, Pharma Intelligence

Osteoporosis Market and Forecast Analysis, Pharma Intelligence

  • $ 22000
  • Industry report
  • January 2019

DISEASE OVERVIEWOsteoporosis is the most common metabolic bone disorder, and is characterized by low bone mass accompanied by microarchitectural deterioration of bone tissue. The consequent increase in ...

  • Industries : Chronic Disease, Pathology, Therapy
  • Countries : United States, Japan, European Union
Diabetes Type 1 Market and Forecast Analysis to 2025

Diabetes Type 1 Market and Forecast Analysis to 2025

  • $ 22000
  • Industry report
  • October 2018

DISEASE OVERVIEWDiabetes mellitus is a group of chronic endocrine disorders characterized by hyperglycemia due to insufficient levels of insulin, a hormone responsible for regulating blood sugar. Type ...

  • Industries : Chronic Disease, Pathology, Therapy
  • Countries : Japan, United States, European Union
Diabetes Type 2 Market and Forecast Analysis to 2024

Diabetes Type 2 Market and Forecast Analysis to 2024

  • $ 22000
  • Industry report
  • October 2018

DISEASE OVERVIEWDiabetes occurs when the body cannot use sugars properly due to impaired insulin production or utilization. Prolonged hyperglycemia (high blood sugar) can lead to serious complications ...

  • Industries : Chronic Disease, Pathology
  • Countries : European Union, United States, Japan
Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025

Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025

  • $ 22000
  • Industry report
  • October 2018

Disease OverviewPulmonary arterial hypertension is one of a group of rare and life-threatening diseases collectively known as pulmonary hypertension (PH). Each PH subgroup shares similar pathophysiology, ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, European Union, Japan
Tracleer

Tracleer

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewTracleer (bosentan; Johnson and Johnson) was the first oral therapy to be developed specifically for the treatment of PH. Tracleer is a competitive endothelin receptor type A and B antagonist, ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Revatio

Revatio

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewRevatio (sildenafil; Pfizer) is a selective inhibitor of the PDE5 enzyme, which enhances the effect of the endogenous vasodilator, nitric oxide. The extracellular vasodilator NO activates ...

  • Industries : Chronic Disease
  • Countries : United States, Japan, European Union
bardoxolone methyl

bardoxolone methyl

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewBardoxolone methyl (AbbVie/Kyowa Hakko Kirin), under development by the research-stage company Reata Pharmaceuticals, is a Phase III candidate in clinical trials for the treatment of pulmonary ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Uptravi

Uptravi

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewUptravi (selexipag; Johnson and Johnson/Nippon Shinyaku) is a first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist. The drug and its active metabolite, ACT-333679, ...

  • Industries : Chronic Disease
  • Countries : United States, Japan, European Union
Opsumit

Opsumit

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewOriginally developed by Actelion, Johnson and Johnson’s Opsumit (macitentan) is the follow-on product to the leading pulmonary hypertension therapy Tracleer. The drug is a next-generation ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Adempas

Adempas

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewAdempas (riociguat; Bayer/Merck and Co) is a first-in-class drug that activates soluble guanylyl cyclase (sGC), a key enzyme in nitric oxide-mediated vasodilation of vascular smooth muscle ...

  • Industries : Drug Development
  • Countries : United States, Japan, European Union
Neuropathic Pain Market and Forecast Analysis to 2026

Neuropathic Pain Market and Forecast Analysis to 2026

  • $ 22000
  • Industry report
  • October 2018

Disease OverviewNeuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system, resulting in symptoms that include burning, stabbing, shooting, or electric shock-like sensations, ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Live-attenuated RSV vaccines

Live-attenuated RSV vaccines

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewIn collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), Sanofi is developing a portfolio of three live-attenuated vaccines (LAVs) for the prevention of serious ...

  • Industries : Chronic Disease
  • Countries : United States, European Union
KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018

KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018

  • $ 2500
  • Industry report
  • September 2018

KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018SummaryThis KOL Insight briefing focuses on KOLs views of Pipeline Therapy Data Presented at EULAR 2018.Questions topics ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Oncology, Chronic Disease, Pathology
  • Countries : United States, European Union
Rheumatoid Arthritis Market and Forecast Analysis to 2025

Rheumatoid Arthritis Market and Forecast Analysis to 2025

  • $ 22000
  • Industry report
  • August 2018

DISEASE OVERVIEWRheumatoid arthritis (RA) is a chronic inflammatory disease that leads to progressive joint deformity, disability, and occasionally premature death. RA may affect many tissues and organs, ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, European Union, Japan
Advair

Advair

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewAdvair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). ...

  • Industries : Therapy, Chronic Disease
  • Countries : United States, Japan, European Union
Spiriva

Spiriva

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewSpiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for use in chronic obstructive pulmonary disease (COPD), and is available in a dry-powde ...

  • Industries : Chronic Disease
  • Countries : United States, Japan, European Union
Trelegy Ellipta

Trelegy Ellipta

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewTrelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Breo Ellipta

Breo Ellipta

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewBreo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Fluticasone ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Tudorza Pressair

Tudorza Pressair

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewTudorza Pressair (aclidinium; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily long-acting muscarinic antagonist indicated for the maintenance treatment of chronic obstructive ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Symbicort

Symbicort

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewAstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting ...

  • Industries : Therapy, Chronic Disease
  • Countries : United States, Japan, European Union
Daliresp

Daliresp

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewDaliresp (roflumilast; AstraZeneca/Allergan/Takeda) is an oral phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of patients with severe chronic obstructive pulmonary disease ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, European Union
Nucala

Nucala

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewNucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
About 200 reports

Download Unlimited Documents from Trusted Public Sources

Neovasc Inc. - Investor Report, January 2020

  • January 2020
    36 pages
  • Angina  

    Hospital  

  • United States  

    European Union  

    World  

View report >

EU Demographic Analysis September 2019


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on